Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-HBV in Healthy Adults and Chronic Hepatitis B Patients
NCT02826018Phase 1Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
Phase 1, randomised, single-blind trial in Chronic Hepatitis B (CHB) comparing ALN-HBV with Placebo (2 arms). Primary endpoint: Proportion of subjects experiencing adverse events at Day 176. Started Jun 2016; status: terminated.
02
Drugs
ALN-HBV
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02826018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826018.